Chemiphar Revises Forecasts Up Following Q3 Performance
Japanese Generics Firm Finally Shaking Off Impact Of NHI Revision And COVID-19
Executive Summary
Three strong quarters in a row have prompted Nippon Chemiphar to revise up its FY2021 forecasts, thanks to strong sales of generic drugs launched in FY2020 and June 2021, as well as an increase in demand due to quality control issues faced by competitors.
You may also be interested in...
Nippon Chemiphar’s Generics Business Continues To Recover
Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
Mifepristone Access Swings In The Balance In Post-Roe World
The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.
Scrap Citizen Petition Proposal For 505(b)(2), Off-Patent Industry Urges FDA
Several stakeholders across the off-patent industry, including trade groups and manufacturers, have encouraged the FDA to scrap its proposal to require companies to submit citizen petitions for requesting therapeutic equivalence evaluations for 505(b)(2) applications.